Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms

Exclusion Criteria

• •A co-morbid condition which, in the view of the Investigator(s), rendered the patient at high risk from treatment complications
• •Failed previous hematopoietic stem cell (HSC) collections or collection attempts
• •Prior autologous or allogeneic transplant
• •Less than 6 weeks off 1,3-bis (2-chloroethyl)-1-nitroso-urea (BCNU) prior to first dose of G-CSF
• •Active central nervous system involvement, active brain metastases, or any history of carcinomatous meningitis (active or inactive)
• •Bone marrow involvement \>20 percent (%), as assessed by bone marrow biopsy within 4 months of the first screening assessment, unless a bone marrow biopsy was performed immediately prior to the last chemotherapy and was negative and the patient responded to last chemotherapy achieving a complete or partial remission
• •Received radiation therapy to the pelvis
• •Received granulocyte/macrophage-colony stimulating factor (GM-CSF) or pegfilgrastim within 3 weeks prior to the first dose of granulocyte colony stimulating factor (G-CSF) for mobilization
• •Received G-CSF within 14 days prior to the first dose of G-CSF for mobilization
• •Received prior radio-immunotherapy with ibritumomab tiuxetan or tositumomab iodine
• •Active infection, including unexplained fever (\>38.1 degree Celsius / 100.4 Fahrenheit), or antibiotic, antiviral, or antifungal therapy within 7 days prior to the first dose of G-CSF
• •Positive pregnancy test (female patients)
• •Lactating (female patients)
• •Abnormal electrocardiogram (ECG) with clinically significant rhythm disturbance (ventricular arrhythmias) or other conduction abnormality in the last year that, in the opinion of the Investigator(s), warranted exclusion of the patient from the trial
• •Previously received experimental therapy within 4 weeks of enrolling or who were currently enrolled in another experimental protocol during the G CSF and plerixafor treatment period